Despite hype around alternative methods, animal models will remain essential in drug development for the foreseeable future. The CEO argues that AI and ML will primarily make these studies more efficient by reducing the number of animals needed and improving data interpretation, not by eliminating the preclinical animal testing stage entirely.
Alloy Therapeutics does not compete on price with international service providers. Instead, it positions itself as a high-quality, domestic partner, structuring deals with milestones and royalties. This premium model attracts partners who prioritize the quality and functionality of the resulting drug asset over securing the lowest-cost service.
Generative AI is not viewed as a standalone solution for drug discovery. Alloy's perspective is that its primary value is in enhancing and automating existing workflows. The model requires a 'lab in the loop' and 'human in the loop,' where AI assists scientists by making them more efficient and improving data analysis, rather than replacing the core wet lab process.
The current success of bi-specific antibodies is not the final stage of antibody therapy. CEO Errik Anderson views it as an iterative learning process. Insights from today's drugs will reveal new unmet needs, leading to the development of next-generation therapies like tri-specifics or different bi-specifics, continuing a decades-long innovation cycle.